Cargando…

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY

Detalles Bibliográficos
Autores principales:	Ghia, Paolo, Allan, John, Siddiqi, Tanya, Wierda, William G., Tam, Constantine, Moreno, Carol, Tedeschi, Alessandra, Szafer-Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, Jim, Szoke, Anita, Barr, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429610/ http://dx.doi.org/10.1097/01.HS9.0000969372.28228.42

Ejemplares similares

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
por: Allan, John N., et al.
Publicado: (2023)

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023)

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
por: Wierda, William G., et al.
Publicado: (2021)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION
por: Kipps, Thomas, et al.
Publicado: (2023)

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
por: Barr, Paul M., et al.
Publicado: (2022)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
por: Eichhorst, Barbara, et al.
Publicado: (2023)

FD&C Yellow No. 6
Publicado: (1982)

An Introduction of FD-Complete Constraints
por: Löffler, Sven, et al.
Publicado: (2020)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Ectopic expression of Arabidopsis FD and FD PARALOGUE in rice results in dwarfism with size reduction of spikelets
por: Jang, Seonghoe, et al.
Publicado: (2017)

Role of the Forkhead Transcription Factors Fd4 and Fd5 During Drosophila Leg Development
por: Ruiz-Losada, Mireya, et al.
Publicado: (2021)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Bilateral breast implant associated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A case report
por: Bletsis, Patrick P., et al.
Publicado: (2020)

Anatomy of $F_D$-Term Hybrid Inflation
por: Garbrecht, Bjorn, et al.
Publicado: (2006)

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
por: Burger, Jan A., et al.
Publicado: (2019)

Filamentous Bacteriophage Fd as an Antigen Delivery System in Vaccination
por: Prisco, Antonella, et al.
Publicado: (2012)

Stereoacuity with Frisby and Revised FD2 Stereo Tests
por: Bohr, Iwo, et al.
Publicado: (2013)

Their C-termini divide Brassica rapa FT-like proteins into FD-interacting and FD-independent proteins that have different effects on the floral transition
por: Lee, Areum, et al.
Publicado: (2023)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
por: Munir, Talha, et al.
Publicado: (2023)

1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)
por: Frei, Michael, et al.
Publicado: (2019)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Physics Simulations of fluids - a brief overview of Phoenix FD
por: Iliev, Ivaylo, et al.
Publicado: (2014)

SCALEUS-FD: A FAIR Data Tool for Biomedical Applications
por: Pereira, Arnaldo, et al.
Publicado: (2020)

BrainFD: Measuring the Intracranial Brain Volume With Fractal Dimension
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Recent Progress in FD-LC-MS/MS Proteomics Method
por: Kobayashi, Hiroshi, et al.
Publicado: (2021)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non‐specific hypersensitivity reactions
por: Abbott, James, et al.
Publicado: (2023)

Corneal Sublayers Thickness Estimation Obtained by High-Resolution FD-OCT
por: Alberto, Diego, et al.
Publicado: (2013)

Combination of 15 lipid metabolites and motilin to diagnose spleen-deficiency FD
por: Zhang, Jiaqi, et al.
Publicado: (2019)

Investigation of Radiation Effects on FD-SOI Hall Sensors by TCAD Simulations
por: Fan, Linjie, et al.
Publicado: (2020)

Erratum: BrainFD: Measuring the Intracranial Brain Volume With Fractal Dimension
por: Frontiers Production Office,
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5npavubuequ7087326p1lqkbef